August 20, 2021
First Patients Treated with INTERCEPT® Fibrinogen Complex
CONCORD, Calif.– Cerus Corporation announced today that the initial set of patients were treated in the U.S. with Cerus’ Pathogen Reduced Cryoprecipitated Fibrinogen Complex, or INTERCEPT® Fibrinogen Complex (IFC), produced from the INTERCEPT® Blood System for Cryoprecipitation, at hospitals associated with a large health system in Los Angeles and Santa Clara, California.
INTERCEPT Fibrinogen Complex is indicated for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. After thawing, INTERCEPT Fibrinogen Complex remains transfusion-ready at room temperature for up to 5 days, continuously available for administration over this extended period. This product was granted FDA Breakthrough Device designation based on the potential to improve treatment of massive hemorrhage, a life-threatening medical condition.
This is an exciting INTERCEPT Fibrinogen Complex milestone and an important step forward in Cerus’ mission to establish pathogen reduction as the standard of care for transfused blood components globally. This is an important win for hospitals, clinicians and patients. In addition to patients in California, soon patients in Texas, Florida, Wisconsin, and Louisiana will have access to this life saving technology.
For more information about INTERCEPT Fibrinogen Complex, visit our product website at www.INTERCEPTFibrinogenComplex.com.
Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT® Blood System for Platelets and Plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. The INTERCEPT red blood cell system is under regulatory review in Europe, and in late-stage clinical development in the US. Also in the US, the INTERCEPT Blood System of Cryoprecipitation is approved for the production of Pathogen Reduced Cryoprecipitated Fibrinogen Complex (commonly referred to as INTERCEPT Fibrinogen Complex), a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. For more information about Cerus, visit www.cerus.com and follow us on LinkedIn.